Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Aikili Biosystems, Inc. is currently navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active case is being reviewed by 1 distinct examiner, DHARITHREESAN, NIDHI, who is the busiest examiner for the portfolio with 1 pending application. The examination is taking place within 1 distinct art unit, reflecting a streamlined prosecution profile.
The presence of 1 pending office action suggests a targeted approach to intellectual property in the Biotechnology & Pharmaceuticals sector. Because the portfolio involves 1 distinct art unit and 1 distinct examiner, the company faces a consolidated set of examiner preferences and technical standards. Successfully addressing the 1 pending application under DHARITHREESAN, NIDHI will be the primary objective for the company's current strategy.
For legal teams, this 1 to 1 ratio of pending actions to examiners allows for a highly focused response. The reliance on 1 distinct examiner, DHARITHREESAN, NIDHI, means that the prosecution outcome is centralized. Practitioners must ensure that the arguments presented in the 1 pending office action align with the specific technical requirements of the 1 distinct art unit involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DHARITHREESAN, NIDHI | 1 | 39.6% | +36.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17642030 | SYSTEMS AND METHODS FOR ARTIFICAL INTELLIGENCE BASED CELL ANALYSIS | DHARITHREESAN, NIDHI | 8d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17642030 | SYSTEMS AND METHODS FOR ARTIFICAL INTELLIGENCE BASED CELL ANALYSIS | DHARITHREESAN, NIDHI | 8d |
| Art Unit | Apps |
|---|---|
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17642030 | SYSTEMS AND METHODS FOR ARTIFICAL INTELLIGENCE BASED CELL ANALYSIS | DHARITHREESAN, NIDHI | 1686 | §101§102§103§112 | Non-Final OA | 8d | Pending | Mar 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial